Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results
Rapid Micro Biosystems (NASDAQ:RPID) reported Q2 2025 financial results, with total revenue reaching $7.3 million, up 10% year-over-year. The company demonstrated strong performance with recurring revenue growing 15% to $4.4 million and service revenue increasing 18% to $2.5 million.
The company secured a significant $45 million term loan facility with Trinity Capital, with $20 million funded at closing. Despite a net loss of $11.9 million, RPID showed improvement in gross margin, reaching positive 4% compared to negative 3% in Q2 2024. The company placed four new Growth Direct systems and completed two system validations during the quarter.
RPID reaffirmed its full-year 2025 revenue guidance of at least $32.0 million. The company ended Q2 with approximately $32 million in cash, cash equivalents, short-term investments, and restricted cash.
Rapid Micro Biosystems (NASDAQ:RPID) ha comunicato i risultati finanziari del secondo trimestre 2025, con ricavi totali pari a $7,3 milioni, in crescita del 10% su base annua. L'azienda ha mostrato una solida performance con ricavi ricorrenti in aumento del 15% a $4,4 milioni e ricavi da servizi saliti del 18% a $2,5 milioni.
L'azienda ha ottenuto un importante fido a termine da $45 milioni con Trinity Capital, di cui $20 milioni erogati alla chiusura. Nonostante una perdita netta di $11,9 milioni, RPID ha migliorato il margine lordo, arrivando a un +4% rispetto al -3% del Q2 2024. Nel trimestre sono stati installati quattro nuovi sistemi Growth Direct e completate due convalide di sistema.
RPID ha riaffermato la sua previsione di ricavi per l'intero 2025 di almeno $32,0 milioni. Al termine del Q2 la societ脿 disponeva di circa $32 milioni in liquidit脿, equivalenti, investimenti a breve termine e contanti vincolati.
Rapid Micro Biosystems (NASDAQ:RPID) present贸 los resultados financieros del 2T 2025, con ingresos totales de $7,3 millones, un aumento del 10% interanual. La compa帽铆a mostr贸 buen desempe帽o con ingresos recurrentes creciendo un 15% hasta $4,4 millones y los ingresos por servicios subiendo un 18% hasta $2,5 millones.
La empresa asegur贸 una l铆nea de pr茅stamo a plazo de $45 millones con Trinity Capital, de la cual $20 millones se desembolsaron al cierre. A pesar de una p茅rdida neta de $11,9 millones, RPID mejor贸 su margen bruto, alcanzando un 4% positivo frente al -3% del 2T 2024. Durante el trimestre se instalaron cuatro nuevos sistemas Growth Direct y se completaron dos validaciones de sistema.
RPID reafirm贸 su gu铆a de ingresos para todo 2025 de al menos $32,0 millones. La compa帽铆a cerr贸 el 2T con aproximadamente $32 millones en efectivo, equivalentes de efectivo, inversiones a corto plazo y efectivo restringido.
Rapid Micro Biosystems (NASDAQ:RPID)電� 2025雲� 2攵勱赴 鞁れ爜鞚� 氚滍憸頄堧嫟. 齑濍Г於滌潃 730毵� 雼煬搿� 鞝勲厔 霃欔赴 雽�牍� 10% 歃濌皜頄堧嫟. 須岇偓電� 氚橂车 毵れ稖鞚� 15% 歃濌皜頃� 440毵� 雼煬毳� 旮半頄堦碃, 靹滊箘鞀� 毵れ稖鞚� 18% 電橃柎 250毵� 雼煬臧� 霅愲嫟.
須岇偓電� Trinity Capital瓿� 頃粯 4,500毵� 雼煬 攴滊鞚� 毵岅赴 雽�於� 鞁滌劋鞚� 頇曤炒頄堨溂氅�, 攴胳 2,000毵� 雼煬臧� 膦呹舶 鞁滌爯鞐� 歆�旮夒悙雼�. 靾滌啇鞁� 1,190毵� 雼煬鞐愲弰 攵堦惮頃橁碃 搁笔滨顿电� 毵れ稖齑濎澊鞚奠澊 臧滌劆霅橃柎 鞝勲厔 霃欔赴 -3%鞐愳劀 鞚措矆 攵勱赴鞐愲姅 +4%搿� 鞝勴櫂頄堧嫟. 攵勱赴 欷� 4雽�鞚� 鞁犼窚 Growth Direct 鞁滌姢韰滌潉 靹れ箻頃橁碃 2瓯挫潣 鞁滌姢韰� 瓴�歃濎潉 鞕勲頄堧嫟.
搁笔滨顿电� 2025雲� 鞝勳泊 毵れ稖 臧�鞚措崢鞀るゼ 斓滌唽 3,200毵� 雼煬搿� 鞛檿鞚疙枅雼�. 須岇偓電� 2攵勱赴 毵� 順勱笀 氚� 順勱笀靹膘瀽靷�, 雼赴韴瀽 氚� 鞝滍暅 順勱笀鞙茧 鞎� 3,200毵� 雼煬毳� 氤挫湢頃橁碃 鞛堨棃雼�.
Rapid Micro Biosystems (NASDAQ:RPID) a publi茅 ses r茅sultats du T2 2025, avec un chiffre d'affaires total de 7,3 M$, en hausse de 10% sur un an. La soci茅t茅 a affich茅 de bonnes performances avec des revenus r茅currents en hausse de 15% 脿 4,4 M$ et des revenus de services en hausse de 18% 脿 2,5 M$.
L'entreprise a obtenu une importante facilit茅 de pr锚t 脿 terme de 45 M$ aupr猫s de Trinity Capital, dont 20 M$ ont 茅t茅 d茅bloqu茅s 脿 la cl么ture. Malgr茅 une perte nette de 11,9 M$, RPID a am茅lior茅 sa marge brute, atteignant +4% contre -3% au T2 2024. Au cours du trimestre, la soci茅t茅 a install茅 quatre nouveaux syst猫mes Growth Direct et finalis茅 deux validations de syst猫me.
RPID a r茅affirm茅 sa pr茅vision de chiffre d'affaires pour 2025 d'au moins 32,0 M$. La soci茅t茅 a termin茅 le T2 avec environ 32 M$ en liquidit茅s, 茅quivalents de tr茅sorerie, placements 脿 court terme et tr茅sorerie restreinte.
Rapid Micro Biosystems (NASDAQ:RPID) meldete die Finanzergebnisse f眉r Q2 2025, wobei die Gesamtums盲tze 7,3 Mio. USD erreichten, ein Anstieg von 10 % gegen眉ber dem Vorjahr. Das Unternehmen zeigte eine starke Entwicklung mit wiederkehrenden Ums盲tzen, die um 15 % auf 4,4 Mio. USD wuchsen, und Serviceums盲tzen, die um 18 % auf 2,5 Mio. USD zunahmen.
Das Unternehmen sicherte sich eine bedeutende Fremdfinanzierungszusage (Term Loan) 眉ber 45 Mio. USD mit Trinity Capital, davon wurden bei Closing 20 Mio. USD ausgezahlt. Trotz eines Nettoverlusts von 11,9 Mio. USD verbesserte RPID die Bruttomarge und erzielte +4 % gegen眉ber -3 % im Q2 2024. Im Quartal wurden vier neue Growth Direct Systeme installiert und zwei Systemvalidierungen abgeschlossen.
RPID best盲tigte erneut seine Umsatzprognose f眉r das Gesamtjahr 2025 von mindestens 32,0 Mio. USD. Zum Ende des Q2 verf眉gte das Unternehmen 眉ber rund 32 Mio. USD an Zahlungsmitteln, Zahlungsmittel盲quivalenten, kurzfristigen Anlagen und gebundenen Geldern.
- Revenue growth of 10% year-over-year to $7.3 million
- Recurring revenue increased 15% to $4.4 million
- Service revenue grew 18% to $2.5 million
- Secured $45 million term loan facility with favorable terms
- Gross margin improved to positive 4% from negative 3% year-over-year
- Operating expenses decreased by 6% to $12.4 million
- Net loss per share improved to $0.27 from $0.29 year-over-year
- Net loss of $11.9 million despite revenue growth
- Fewer system validations (2) compared to Q2 2024 (5)
- Fewer Growth Direct system placements (4) compared to Q2 2024 (5)
- Cash position of $32 million may require additional financing despite new loan facility
Insights
Rapid Micro shows modest 10% revenue growth with improving margins, but still operates at significant losses despite securing new financing.
Rapid Micro Biosystems' Q2 results paint a mixed picture with modest improvements alongside persistent challenges. The company achieved $7.3 million in quarterly revenue, reflecting 10% year-over-year growth, with recurring revenue increasing at a healthier 15% rate to reach $4.4 million. This recurring revenue component, now representing approximately 60% of total revenue, provides some stability to their business model.
The most encouraging sign is the gross margin improvement, which turned positive at 4% compared to negative 3% in Q2 2024 - a 7 percentage point improvement. This suggests their efficiency initiatives are beginning to yield results, though margins remain dangerously thin for a technology company.
However, significant concerns persist. Despite reducing operating expenses by 6% to $12.4 million, the company still posted a substantial net loss of $11.9 million for the quarter. While this represents a slight improvement from the $12.6 million loss in Q2 2024, the company continues to burn cash at an alarming rate relative to its revenue base.
The newly secured $45 million term loan facility (with $20 million funded upfront) provides critical runway, considering their $32 million cash position as of June 30. However, this additional debt adds financial burden and underscores their continued reliance on external financing rather than operational self-sufficiency.
With management reaffirming full-year revenue guidance of at least $32 million, the company projects modest annual growth. However, the fundamental challenge remains: generating sufficient revenue and margin improvement to significantly reduce operating losses and eventually achieve positive cash flow before their capital resources are exhausted.
- Reports second quarter 2025 total revenue of
$7.3 million , representing10% growth compared to the second quarter of 2024.- Second quarter 2025 recurring revenue increased
15% compared to the second quarter of 2024.
- Second quarter 2025 recurring revenue increased
- Reports second quarter gross margin of
4% , representing a seven-percentage point improvement compared to the second quarter of 2024.
- Enters into five-year,
$45 million term loan facility with$20 million funded at close.
- Reaffirms full-year 2025 total revenue guidance of at least
$32.0 million .
LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the 鈥淐ompany鈥�), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June听30, 2025.
鈥淥ur second quarter results reflect broad-based, consistent execution across the business,鈥� said Robert Spignesi, President and CEO. 鈥淭otal revenue increased
鈥淚n addition, this morning we announced a new five-year,
Second Quarter Financial Results
Total revenue for the second quarter of 2025 increased
Total cost of revenue was
Total operating expenses decreased by
Net loss for the second quarter of 2025 was
Cash, cash equivalents, short-term investments, and restricted cash were approximately
2025 Outlook
The Company is reaffirming its full year 2025 total revenue guidance of at least
Loan Facility
In a separate release issued today, the Company announced that it has entered into a five-year,
For additional details regarding this facility, please refer to the related press release at .
Webcast Details
The Company will host a conference call before the market opens today, August听12, 2025, at 8:30 a.m. ET to discuss its second quarter 2025 financial results. The live call is accessible on the Company鈥檚 website at听 and will be archived and available for replay for one year.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company鈥檚 flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (鈥淢QC鈥�) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit 听or follow the Company on X (formerly known as Twitter) at听 or on .
Rapid Micro Biosystems intends to use the Investor Relations page of its website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor its website in addition to following press releases, filings with the Securities and Exchange Commission (鈥淪EC鈥�), public conference calls, presentations and webcasts.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company鈥檚 guidance, including with respect to full year 2025 total revenue and number of Growth Direct placements; the Company's goal of achieving cash flow breakeven; the Company's newly-announced debt facility; the Company鈥檚 ability to reduce product costs, and improve manufacturing efficiency and service productivity; and the Company's ability to advance its priorities of accelerating Growth Direct system placements, improving gross margins and innovating new products.
In some cases, you can identify forward-looking statements by terminology such as 鈥渙utlook,鈥� 鈥渁im,鈥� 鈥渁nticipate,鈥� 鈥渁ssume,鈥� 鈥渂elieve,鈥� 鈥渃ontemplate,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渄ue,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥済oal,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渙bjective,鈥� 鈥減lan,鈥� 鈥減redict,鈥� 鈥減otential,鈥� 鈥減ositioned,鈥� 鈥渟eek,鈥� 鈥渟hould,鈥� 鈥渢arget,鈥� 鈥渨ill,鈥� 鈥渨ould鈥� and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to risks related to, the Company's ability to achieve positive cash flow; the Company's ability to achieve its business objectives; the Company's significant losses since inception; the Company鈥檚 ability to meet its publicly announced guidance and other expectations about its business and operations; the impact of the Company's existing and any future indebtedness on its ability to operate its business; the Company鈥檚 ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder, the Company鈥檚 limited experience in marketing and sales and the effectiveness of its sales processes; the Company鈥檚 need to develop new products and adapt to technological changes; the Company鈥檚 ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company鈥檚 ability to maintain its manufacturing facility; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company鈥檚 ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; risks associated with macroeconomic events and uncertainty, including with respect to tariff and trade policy in the U.S. and abroad, as well as activity in the Company's industry and in the general economy; and the other important factors outlined under the caption 鈥淩isk Factors鈥� in the Company鈥檚 Quarterly Report on Form 10-Q filed with the SEC, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
| RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) | ||||||||||||||||
| 听 | ||||||||||||||||
| 听 | Three Months Ended June 30, | 听 | Six Months Ended June 30, | 听 | ||||||||||||
| 听 | 2025 | 听 | 2024 | 听 | 2025 | 听 | 2024 | 听 | ||||||||
| Revenue: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Product revenue | $ | 4,802 | 听 | 听 | $ | 4,537 | 听 | 听 | $ | 8,903 | 听 | 听 | $ | 8,250 | 听 | 听 |
| Service revenue | 听 | 2,460 | 听 | 听 | 听 | 2,081 | 听 | 听 | 听 | 5,564 | 听 | 听 | 听 | 3,979 | 听 | 听 |
| Total revenue | 听 | 7,262 | 听 | 听 | 听 | 6,618 | 听 | 听 | 听 | 14,467 | 听 | 听 | 听 | 12,229 | 听 | 听 |
| Costs and operating expenses: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Cost of product revenue | 听 | 5,315 | 听 | 听 | 听 | 4,917 | 听 | 听 | 听 | 10,344 | 听 | 听 | 听 | 10,090 | 听 | 听 |
| Cost of service revenue | 听 | 1,672 | 听 | 听 | 听 | 1,890 | 听 | 听 | 听 | 3,444 | 听 | 听 | 听 | 3,851 | 听 | 听 |
| Research and development | 听 | 3,230 | 听 | 听 | 听 | 3,744 | 听 | 听 | 听 | 6,854 | 听 | 听 | 听 | 7,586 | 听 | 听 |
| Sales and marketing | 听 | 3,114 | 听 | 听 | 听 | 3,627 | 听 | 听 | 听 | 5,865 | 听 | 听 | 听 | 6,908 | 听 | 听 |
| General and administrative | 听 | 6,079 | 听 | 听 | 听 | 5,818 | 听 | 听 | 听 | 11,769 | 听 | 听 | 听 | 11,445 | 听 | 听 |
| Total costs and operating expenses | 听 | 19,410 | 听 | 听 | 听 | 19,996 | 听 | 听 | 听 | 38,276 | 听 | 听 | 听 | 39,880 | 听 | 听 |
| Loss from operations | 听 | (12,148 | ) | 听 | 听 | (13,378 | ) | 听 | 听 | (23,809 | ) | 听 | 听 | (27,651 | ) | 听 |
| Other income (expense): | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Interest income, net | 听 | 351 | 听 | 听 | 听 | 838 | 听 | 听 | 听 | 817 | 听 | 听 | 听 | 1,821 | 听 | 听 |
| Other expense, net | 听 | (50 | ) | 听 | 听 | (23 | ) | 听 | 听 | (111 | ) | 听 | 听 | (52 | ) | 听 |
| Total other income, net | 听 | 301 | 听 | 听 | 听 | 815 | 听 | 听 | 听 | 706 | 听 | 听 | 听 | 1,769 | 听 | 听 |
| Loss before income taxes | 听 | (11,847 | ) | 听 | 听 | (12,563 | ) | 听 | 听 | (23,103 | ) | 听 | 听 | (25,882 | ) | 听 |
| Income tax expense | 听 | 11 | 听 | 听 | 听 | 15 | 听 | 听 | 听 | 18 | 听 | 听 | 听 | 18 | 听 | 听 |
| Net loss | $ | (11,858 | ) | 听 | $ | (12,578 | ) | 听 | 听 | (23,121 | ) | 听 | 听 | (25,900 | ) | 听 |
| Net loss per share 鈥� basic and diluted | $ | (0.27 | ) | 听 | $ | (0.29 | ) | 听 | $ | (0.52 | ) | 听 | $ | (0.60 | ) | 听 |
| Weighted average common shares outstanding 鈥� basic and diluted | 听 | 44,648,602 | 听 | 听 | 听 | 43,616,501 | 听 | 听 | 听 | 44,321,566 | 听 | 听 | 听 | 43,431,170 | 听 | 听 |
| 听 | ||||||||||||||||
| RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Balance Sheets (in thousands) | ||||||
| 听 | ||||||
| 听 | June 30, 2025 | 听 | December 31, 2024 | 听 | ||
| Assets | 听 | 听 | 听 | 听 | 听 | 听 |
| Current assets: | 听 | 听 | 听 | 听 | 听 | 听 |
| Cash and cash equivalents | $ | 18,333 | 听 | $ | 16,911 | 听 |
| Short-term investments | 听 | 12,922 | 听 | 听 | 33,821 | 听 |
| Accounts receivable | 听 | 6,048 | 听 | 听 | 7,519 | 听 |
| Inventory | 听 | 20,560 | 听 | 听 | 20,200 | 听 |
| Prepaid expenses and other current assets | 听 | 2,283 | 听 | 听 | 2,466 | 听 |
| Total current assets | 听 | 60,146 | 听 | 听 | 80,917 | 听 |
| Property and equipment, net | 听 | 10,205 | 听 | 听 | 11,193 | 听 |
| Right-of-use assets, net | 听 | 4,640 | 听 | 听 | 5,163 | 听 |
| Other long-term assets | 听 | 311 | 听 | 听 | 531 | 听 |
| Restricted cash | 听 | 284 | 听 | 听 | 365 | 听 |
| Total assets | $ | 75,586 | 听 | $ | 98,169 | 听 |
| Liabilities and Stockholders鈥� Equity | 听 | 听 | 听 | 听 | 听 | 听 |
| Current liabilities: | 听 | 听 | 听 | 听 | 听 | 听 |
| Accounts payable | $ | 3,334 | 听 | $ | 2,535 | 听 |
| Accrued expenses and other current liabilities | 听 | 5,678 | 听 | 听 | 7,217 | 听 |
| Deferred revenue | 听 | 6,136 | 听 | 听 | 6,599 | 听 |
| Lease liabilities, short-term | 听 | 1,255 | 听 | 听 | 1,214 | 听 |
| Total current liabilities | 听 | 16,403 | 听 | 听 | 17,565 | 听 |
| Lease liabilities, long-term | 听 | 4,324 | 听 | 听 | 4,954 | 听 |
| Other long-term liabilities | 听 | 314 | 听 | 听 | 298 | 听 |
| Total liabilities | 听 | 21,041 | 听 | 听 | 22,817 | 听 |
| Total stockholders鈥� equity | 听 | 54,545 | 听 | 听 | 75,352 | 听 |
| Total liabilities and stockholders鈥� equity | $ | 75,586 | 听 | $ | 98,169 | 听 |
| 听 | ||||||
| RAPID MICRO BIOSYSTEMS, INC. Unaudited Cash, Cash Equivalents and Investments (in thousands) | ||||||
| 听 | ||||||
| 听 | June 30, 2025 | 听 | December 31, 2024 | 听 | ||
| Cash and cash equivalents | $ | 18,333 | 听 | $ | 16,911 | 听 |
| Short-term investments | 听 | 12,922 | 听 | 听 | 33,821 | 听 |
| Cash, cash equivalents and investments | $ | 31,255 | 听 | $ | 50,732 | 听 |
Investor Contact Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications [email protected] Media Contact [email protected]
FAQ
What were Rapid Micro Biosystems (RPID) Q2 2025 earnings results?
How much was RPID's new term loan facility and what are the terms?
What is RPID's revenue guidance for 2025?
How many Growth Direct systems did RPID place in Q2 2025?
What was RPID's recurring revenue growth in Q2 2025?
